Cantourage Group SEXTER:HIGH +0.97%24 Altman Z-Score is 11.29 as of Jun. 30, 2026, which is 89% below its 10-year median of 98.19. GuruFocus rates XTER:HIGH with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 949 Drug Manufacturers companies, Cantourage Group SE ranks better than 86.2% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 10.19 is strong.
Cantourage Group SE has a Altman Z-Score of 11.29, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Cantourage Group SE's Altman Z-Score or its related term are showing as below:
XTER:HIGH'
s Altman Z-Score Range Over the Past 10 Years
Min: 10.19 Med: 98.19 Max: 183.29
Current: 10.19
During the past 5 years, Cantourage Group SE's highest Altman Z-Score was 183.29. The lowest was 10.19. And the median was 98.19.
Cantourage Group SE (XTER:HIGH) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Cantourage Group SE Altman Z-Score Related Terms
Cantourage Group SE Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Cantourage Group SE's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:HIGH vs ZTS, UTHR, VTRS: Altman Z-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cantourage Group SE's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantourage Group SE Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cantourage Group SE's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Cantourage Group SE's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Cantourage Group SE's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.0911
+
1.4
*
-0.0965
+
3.3
*
-0.0978
+
0.6
*
18.5109
+
1.0
*
0.5332
=
11.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Cantourage Group SE (XTER:HIGH) has a Altman Z-Score of 11.29 as of Jun. 30, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Cantourage Group SE and its competitors. This is 89% below median its historical median of 98.19. Over the past decade, Cantourage Group SE's Altman Z-Score has ranged from 10.19 to 183.29. According to the industry distribution chart, Cantourage Group SE ranks #131 out of 949 companies in the Drug Manufacturers industry, placing it in the top 13.8%.
Is Cantourage Group SE's Altman Z-Score too high?
Cantourage Group SE's current Altman Z-Score of 11.29 is 89% below median its 10-year median of 98.19. Over the past 10 years, this metric has ranged from a low of 10.19 to a high of 183.29. The Drug Manufacturers industry median Altman Z-Score is 3.20. Cantourage Group SE's value of 11.29 is 252.8% above this industry median. Based on the distribution chart, Cantourage Group SE ranks #131 out of 949 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cantourage Group SE has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Cantourage Group SE's Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cantourage Group SE ranks #131 out of 949 companies for Altman Z-Score. This places Cantourage Group SE in the top 14% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.20. Cantourage Group SE's value of 11.29 is 252.8% above this benchmark. Historically, Cantourage Group SE's own Altman Z-Score has ranged from 10.19 to 183.29 over the past decade. While the company's 10-year median is 98.19 vs. the industry median of 3.20, Cantourage Group SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.20, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantourage Group SE's current Altman Z-Score of 11.29 is 252.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Cantourage Group SE and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantourage Group SE's current Altman Z-Score is 11.29, which is 89% below median its own 10-year median of 98.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantourage Group SE stock overvalued right now?
Cantourage Group SE (XTER:HIGH) has a current Altman Z-Score of 11.29. The current Altman Z-Score is 11.29, which is 89% below median its 10-year median of 98.19 and 252.8% above the Drug Manufacturers industry median of 3.20. Cantourage Group SE's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Cantourage Group SE (XTER:HIGH), the current Altman Z-Score is 11.29 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantourage Group SE is engaged in the manufacture and wholesale of medicinal preparations based on cannabis and the trade and distribution of other legally permissible cannabis products, medical devices, pharmaceuticals, and accessories. The group offers cannabis flowers, dronabinol, CBD, and extracts of various strains.
24GF Score
Get the complete analysis for XTER:HIGH
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HIGH has been successfully added to your 
